Gillessen, Silke; Bossi, Alberto; Davis, Ian D; de Bono, Johann; Fizazi, Karim; James, Nicholas D; Mottet, Nicolas; Shore, Neal; Small, Eric; Smith, Matthew; Sweeney, Christopher J; Tombal, Bertrand; Antonarakis, Emmanuel S; Aparicio, Ana M; Armstrong, Andrew J; Attard, Gerhardt; Beer, Tomasz M; Beltran, Himisha; Bjartell, Anders; Blanchard, Pierre; ... (2023). Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. European journal of cancer, 185, pp. 178-215. Elsevier 10.1016/j.ejca.2023.02.018
|
Text
1-s2.0-S0959804923001107-main.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (1MB) | Preview |
BACKGROUND
Innovations in imaging and molecular characterisation together with novel treatment options have improved outcomes in advanced prostate cancer. However, we still lack high-level evidence in many areas relevant to making management decisions in daily clinical practise. The 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) addressed some questions in these areas to supplement guidelines that mostly are based on level 1 evidence.
OBJECTIVE
To present the voting results of the APCCC 2022.
DESIGN, SETTING, AND PARTICIPANTS
The experts voted on controversial questions where high-level evidence is mostly lacking: locally advanced prostate cancer; biochemical recurrence after local treatment; metastatic hormone-sensitive, non-metastatic, and metastatic castration-resistant prostate cancer; oligometastatic prostate cancer; and managing side effects of hormonal therapy. A panel of 105 international prostate cancer experts voted on the consensus questions.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
The panel voted on 198 pre-defined questions, which were developed by 117 voting and non-voting panel members prior to the conference following a modified Delphi process. A total of 116 questions on metastatic and/or castration-resistant prostate cancer are discussed in this manuscript. In 2022, the voting was done by a web-based survey because of COVID-19 restrictions.
RESULTS AND LIMITATIONS
The voting reflects the expert opinion of these panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results are reported in the supplementary material. We report here on topics in metastatic, hormone-sensitive prostate cancer (mHSPC), non-metastatic, castration-resistant prostate cancer (nmCRPC), metastatic castration-resistant prostate cancer (mCRPC), and oligometastatic and oligoprogressive prostate cancer.
CONCLUSIONS
These voting results in four specific areas from a panel of experts in advanced prostate cancer can help clinicians and patients navigate controversial areas of management for which high-level evidence is scant or conflicting and can help research funders and policy makers identify information gaps and consider what areas to explore further. However, diagnostic and treatment decisions always have to be individualised based on patient characteristics, including the extent and location of disease, prior treatment(s), co-morbidities, patient preferences, and treatment recommendations and should also incorporate current and emerging clinical evidence and logistic and economic factors. Enrolment in clinical trials is strongly encouraged. Importantly, APCCC 2022 once again identified important gaps where there is non-consensus and that merit evaluation in specifically designed trials.
PATIENT SUMMARY
The Advanced Prostate Cancer Consensus Conference (APCCC) provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference aims to share the knowledge of international experts in prostate cancer with healthcare providers worldwide. At each APCCC, an expert panel votes on pre-defined questions that target the most clinically relevant areas of advanced prostate cancer treatment for which there are gaps in knowledge. The results of the voting provide a practical guide to help clinicians discuss therapeutic options with patients and their relatives as part of shared and multidisciplinary decision-making. This report focuses on the advanced setting, covering metastatic hormone-sensitive prostate cancer and both non-metastatic and metastatic castration-resistant prostate cancer.
TWITTER SUMMARY
Report of the results of APCCC 2022 for the following topics: mHSPC, nmCRPC, mCRPC, and oligometastatic prostate cancer.
TAKE-HOME MESSAGE
At APCCC 2022, clinically important questions in the management of advanced prostate cancer management were identified and discussed, and experts voted on pre-defined consensus questions. The report of the results for metastatic and/or castration-resistant prostate cancer is summarised here.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) |
UniBE Contributor: |
Rubin, Mark Andrew |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1879-0852 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Andrea Stettler |
Date Deposited: |
03 Jan 2024 12:07 |
Last Modified: |
03 Jan 2024 12:16 |
Publisher DOI: |
10.1016/j.ejca.2023.02.018 |
PubMed ID: |
37003085 |
Uncontrolled Keywords: |
Androgen receptor pathway inhibitors (ARPI) Chemotherapy Hormonal treatment Metastatic castration-resistant prostate cancer (mCRPC) and oligometastatic and oligoprogressive prostate cancer Metastatic hormone-sensitive prostate cancer (mHSPC) Next-generation imaging Non metastatic castration-resistant prostate cancer (nmCRPC) PSMA PET-imaging Systemic therapy |
BORIS DOI: |
10.48350/191102 |
URI: |
https://boris.unibe.ch/id/eprint/191102 |
Actions (login required)
 |
Edit item |